> Detailanzeige

Fernández, Marcelo Sanmartín; Marín, Francisco; Rafols, Carles; Arribas, Fernando; Barrios, Vivencio; Cosín-Sales, Juan; Sánchez, Manuel Anguita; Pérez Cabeza, Alejandro; Tercedor, Luis; Gamez Lopez, Antonio Luis; Ruiz, Martín; Cortez Quiroga, Gustavo; Arrebola Moreno, Antonio Luis; Lopez Sanchez, Eduardo Sebastian; Torres Llergo, Javier; Motero Carrasco, Juan; Sáinz Hidalgo, Ignacio; Pérez Muñoz, Carlos; Bolea Lafont, Adolfo; Barón Esquivas, Gonzalo; Francisco Monzón, Jose; Renilla González, Alfredo; Valverde Andre, Irene; Ripoll Vera, Tomás; [...]

Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study)

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study)
  • Beteiligte: Fernández, Marcelo Sanmartín; Marín, Francisco; Rafols, Carles; Arribas, Fernando; Barrios, Vivencio; Cosín-Sales, Juan; Sánchez, Manuel Anguita; Pérez Cabeza, Alejandro; Tercedor, Luis; Gamez Lopez, Antonio Luis; Ruiz, Martín; Cortez Quiroga, Gustavo; Arrebola Moreno, Antonio Luis; Lopez Sanchez, Eduardo Sebastian; Torres Llergo, Javier; Motero Carrasco, Juan; Sáinz Hidalgo, Ignacio; Pérez Muñoz, Carlos; Bolea Lafont, Adolfo; Barón Esquivas, Gonzalo; Francisco Monzón, Jose; Renilla González, Alfredo; Valverde Andre, Irene; Ripoll Vera, Tomás; [...]
  • Erschienen: Becaris Publishing Limited, 2021
  • Erschienen in: Journal of Comparative Effectiveness Research
  • Sprache: Englisch
  • DOI: 10.2217/cer-2020-0286
  • ISSN: 2042-6305; 2042-6313
  • Schlagwörter: Health Policy
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> <jats:bold>Aim:</jats:bold> To analyze the frequency and variables related to inappropriate rivaroxaban dosage in clinical practice and its impact on outcomes after 2 years. <jats:bold>Materials &amp; methods:</jats:bold> Postauthorization, observational, multicenter study, in which atrial fibrillation patients, treated with rivaroxaban ≥6 months were included. <jats:bold>Results:</jats:bold>  A total of 1421 patients (74.2 ± 9.7 years, CHA <jats:sub>2</jats:sub> DS <jats:sub>2</jats:sub> -VASc 3.5 ± 1.6) were included. Overall, 22.9% received rivaroxaban 15 mg. The proper dose of rivaroxaban was taken by 83.3% (9.7% underdosed, 7.0% overdosed). Older age and renal insufficiency were associated with inadequate rivaroxaban dosage. There was a trend toward higher all-cause mortality among underdosed patients (adjusted hazard ratio 1.39; 95% CI 0.75–2.58), and more bleedings in overdosed patients (2.29 vs 0.80 events/100 patient-years; p = 0.14). <jats:bold>Conclusion:</jats:bold> In clinical practice, rivaroxaban is properly dosed in most patients. </jats:p>
  • Zugangsstatus: Freier Zugang